Sign in

    Mike King

    Managing Director and Senior Biotechnology Analyst at H.C. Wainwright & Co., LLC

    Michael G. King, Jr. is a Managing Director and Senior Biotechnology Analyst at H.C. Wainwright & Co., specializing in life sciences equity research with a primary focus on biotechnology companies. Throughout his extensive career, he has covered prominent names within the biotech sector and has been recognized for his research performance, earning accolades such as The Wall Street Journal's 'Best on the Street 2014' and Institutional Investor's 'Home Run Hitter 2000.' King joined H.C. Wainwright in early 2021 after serving as Entrepreneur in Residence at Fortress Biotech and holding senior analytical roles at JMP Securities, Rodman & Renshaw (Director of Research), Banc of America Securities, Dillon, Read & Co., Vector Securities, and Robertson Stephens over a 25-year span. He holds a BA in finance from Baruch College and maintains FINRA registration, bringing deep experience in equity research and capital markets to his current role.

    Mike King's questions to Salarius Pharmaceuticals (SLRX) leadership

    Mike King's questions to Salarius Pharmaceuticals (SLRX) leadership • Q3 2021

    Question

    Mike King of H.C. Wainwright & Co., LLC asked about the clinical strategy for seclidemstat in combination with pembrolizumab in gynecologic cancers, including the target patient population, line of treatment, and study design elements to ensure the benefit of seclidemstat is clear. He also asked if biomarker work would be included.

    Answer

    SVP of Clinical Development Nadeem Mirza stated the investigator-sponsored study will initially target relapsed/refractory patients to find the recommended Phase 2 dose. He described it as a proof-of-concept study that could open doors to other tumor types where checkpoint inhibitors are used. Mirza also confirmed that all Salarius studies have a biomarker component.

    Ask Fintool Equity Research AI